112 patents
Utility
Combination of Vaccination and Inhibition of the PD-1 Pathway
25 May 23
The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2.
Mariola FOTIN-MLECZEK, Karl-Josef KALLEN, Jochen PROBST
Filed: 24 Aug 22
Utility
Rotavirus Vaccines
27 Apr 23
The present invention provides mRNA sequences comprising at least one coding region, encoding for at least one epitope of a protein, or of a fragment, variant or derivative thereof, of a virus of the genus rotavirus.
Susanne RAUCH, Benjamin PETSCH
Filed: 7 Jul 22
Utility
Lipid Nanoparticles for Delivery of Nucleic Acids
23 Mar 23
The application relates to cationic lipids and to compositions comprising said cationic lipids useful for the delivery of nucleic acids into living cells.
Gemma NAVARRO, Patrick BAUMHOF
Filed: 18 Dec 20
Utility
Dry powder composition comprising long-chain RNA
27 Dec 22
The present invention is directed to a storage-stable formulation of long-chain RNA.
Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
Filed: 18 Jun 20
Utility
NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT
22 Dec 22
The present invention relates to nucleic acids of the general formula (I): (NuGlXmGnNv)a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant.
Thomas KRAMPS, Söhnke VOSS, Jochen PROBST, Ingmar HOERR
Filed: 29 Jun 22
Utility
Coronavirus Vaccine
15 Dec 22
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19.
Susanne RAUCH, Hans Wolfgang GROßE, Benjamin PETSCH
Filed: 9 Aug 22
Utility
Rna for Cancer Therapy
15 Dec 22
The present invention relates to RNA, particularly an immunostimulatory RNA (isRNA), a coding RNA or a combination thereof, for use in the treatment or prophylaxis of a disease, in particular a tumor and/or cancer disease.
Mariola FOTIN-MLECZEK, Aleksandra KOWALCZYK, Regina HEIDENREICH, Ulrike GNAD-VOGT, Ute KLINKHARDT, Katja FIEDLER
Filed: 10 Jan 22
Utility
Dry Powder Composition Comprising Long-chain Rna
8 Dec 22
The present invention is directed to a storage-stable formulation of long-chain RNA.
Fabian Johannes EBER, Benyamin YAZDAN PANAH, Stefanie SEWING, Thomas KETTERER, Thorsten MUTZKE, Tilmann ROOS, Michael SONNTAG, Michael WIGGENHORN, Katharina KOLLAND
Filed: 11 Jul 22
Utility
Method for In Vitro Transcription Using an Immobilized Restriction Enzyme
8 Dec 22
The present invention relates to a method for in vitro transcription of a linear template DNA which is produced using an immobilized restriction endonuclease.
Tilmann ROOS, Benyamin YAZDAN PANAH, Martin KUNZE
Filed: 17 Aug 22
Utility
Rna-coded Antibody
24 Nov 22
The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy.
Ingmar HOERR, Jochen PROBST, Steve PASCOLO
Filed: 19 Jul 22
Utility
Immobilized Poly(n)polymerase
3 Nov 22
The present invention relates to an immobilized poly(N)polymerase (PNP), methods of producing said PNP and uses thereof.
Tilmann ROOS, Benyamin YAZDAN PANAH, Markus CONZELMANN, Veronika WAGNER
Filed: 13 Jun 22
Utility
Kras Variant Mrna Molecules
27 Oct 22
The present invention provides an mRNA molecule encoding at least one KRAS variant peptide.
Amit AGGARWAL, Katja FIEDLER, Ulrike GNAD-VOGT, Regina HEIDENREICH, Mythili KONERU, Gregory D. PLOWMAN
Filed: 6 Dec 19
Utility
Hybrid carriers for nucleic acid cargo
25 Oct 22
A composition for the delivery of a nucleic acid compound is provided which comprises a cationic peptide or polymer and a lipidoid compound.
Patrick Baumhof, Carolin Thiele, Joanna Rejman
Filed: 9 Jun 17
Utility
RNA vaccine against SARS-CoV-2 variants
20 Oct 22
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19.
Nicole ROTH, Diego Chaves MORENO, Hans Wolfgang GROßE, Dominik VAHRENHORST, Susanne RAUCH
Filed: 31 May 22
Utility
Coronavirus vaccine
18 Oct 22
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19.
Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
Filed: 9 Dec 21
Utility
RNA for treatment or prophylaxis of a liver disease
11 Oct 22
The present invention relates to an RNA suitable for treatment or prophylaxis of liver diseases.
Nigel Horscroft, Marion Pönisch, Christine Weinl-Tenbruck, Frédéric Chevessier-Tünnesen
Filed: 8 Dec 17
Utility
Lassa virus vaccine
11 Oct 22
The present invention provides mRNAs usable as vaccines against lassa virus (LASV) infections.
Edith Jasny, Benjamin Petsch
Filed: 22 Dec 17
Utility
Rotavirus Mrna Vaccine
6 Oct 22
The invention is directed to a coding RNA for a Rotavirus vaccine.
Susanne RAUCH, Sandro ROIER, Benjamin PETSCH
Filed: 18 Jun 20
Utility
Combination of vaccination and inhibition of MHC class I restricted antigen presentation
4 Oct 22
The present invention relates to a vaccine/inhibitor combination comprising as a vaccine at least one antigen and as an inhibitor at least one inhibitor of the major histocompatibility complex (MHC) class I restricted antigen presentation.
Christina Lorenz, Mariola Fotin-Mleczek, Karl-Josef Kallen
Filed: 21 Jul 17
Utility
Combination of vaccination and inhibition of the PD-1 pathway
4 Oct 22
The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2.
Mariola Fotin-Mleczek, Karl-Josef Kallen, Jochen Probst
Filed: 29 Aug 19